Molbio Diagnostics IPO Details
MAINBOARD
Molbio Diagnostics IPO DRHP (Draft Red Herring Prospectus) has been SEBI Approval Received.
Offer for Sale consists of 1,25,56,000 shares .
The Lead Managers for Molbio Diagnostics IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is IIFL Capital Services Ltd, Kotak Mahindra Capital Company Ltd, Jefferies India Pvt Ltd, Motilal Oswal Investment Advisors Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Molbio Diagnostics Limited DRHP.
Molbio Diagnostics IPO Details
Molbio Diagnostics IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Molbio Diagnostics IPO Reservation
Promoter Holding
Documents
Molbio Diagnostics IPO Valuations
Molbio Diagnostics Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 1,034.21 | 1,221.06 | 1,461.56 |
| Total Income | 1,027.94 | 840.66 | 337.41 |
| Profit After Tax | 138.58 | 83.54 | -3.45 |
| EBITDA | 256.64 | 185.09 | 48.11 |
| Net Worth | 952.95 | 807.94 | 706.04 |
| Total Borrowing | 123.16 | 174.58 | 108.44 |
| Amount in ₹ Crore | |||
About Molbio Diagnostics IPO
Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care (“POC”) diagnostics company focused on delivering accurate, rapid, and cost-effective healthcare technologies for infectious and non-communicable diseases.
The company has developed the ‘Truenat’ platform, a portable polymerase chain reaction (“PCR”) system that provides decentralized diagnosis within an hour, even in resource-limited settings. As of March 31, 2025, the platform is patented in over 100 countries and offers molecular testing for 30 diseases, including tuberculosis (TB), COVID, Hepatitis B and C, HIV, and HPV through 42 assays. The ‘Truenat’ TB test is one of only two WHO-endorsed rapid molecular tests for initial TB diagnosis and rifampicin resistance detection.
The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiary Prognosys, associate OptraScan, and collaboration partner UE Lifesciences.
The company operates five manufacturing facilities in India – two in Goa, one in Visakhapatnam (Andhra Pradesh), and two in Bengaluru (Karnataka). These units manufacture diagnostic devices, test kits, and radiology products such as ultraportable and mobile X-ray systems.
The company has a global presence in over 80 countries with 33 international distributors and has sold more than 10,000 devices as of March 31, 2025. Products are supplied directly and through distributors to public health programs, diagnostic laboratories, and hospitals.
The company generates revenues from device sales as well as recurring revenues from proprietary test kits.
As of March 31, 2025, the company employed 1,000 permanent employees and 1,511 contract labourers.
Strength Of Molbio Diagnostics IPO
Risk Of Molbio Diagnostics IPO
Objectives Molbio Diagnostics IPO
1. Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space.
2. Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and
3. General corporate purposes
Company Contact Details
Molbio Diagnostics Ltd.
Plot No. L-46
Phase II-D, Verna Industrial Area
Verna, Salcete
South Goa, Goa, 403722
Phone: +91 8326724888
Email: investors@molbiodiagnostics.com
Website: http://www.molbiodiagnostics.com/
Registrar Contact Details
Molbio Diagnostics IPO - FAQs
The Molbio Diagnostics IPO is a MAINBOARD public issue comprising 0 equity shares with a face value of ₹1 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
Kfin Technologies Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.